Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Suven Pharmaceuticals Ltd. ( (IN:COHANCE) ) is now available.
Cohance Lifesciences has approved the grant of 198,711 stock options to eligible employees of the company and its subsidiaries under its Employee Stock Option Plan 2023. The options, which are compliant with SEBI’s share-based benefit regulations, will vest between one and ten years from the grant date and may be exercised within three years of vesting, underscoring the company’s use of long-term incentives to align employee interests with shareholder value and support talent retention.
Each option entitles the holder to apply for one equity share of face value Re 1, with pricing set as per the ESOP 2023 framework. The move is expected to modestly expand the company’s equity base upon exercise while reinforcing its compensation structure in line with regulatory norms and common capital market practices in India’s pharmaceutical and lifesciences industry.
More about Suven Pharmaceuticals Ltd.
Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, operates in the lifesciences and pharmaceuticals sector. The company focuses on providing pharmaceutical products and services, supported by its subsidiaries, and uses share-based compensation schemes to attract and retain key employees across its operations.
Average Trading Volume: 79,469
Technical Sentiment Signal: Sell
Current Market Cap: 110.8B INR
See more insights into COHANCE stock on TipRanks’ Stock Analysis page.